Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Kalydeco“
Suchtreffer
Begriffe & Kennungen
Kalydeco · 4.5 · In vitro studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolite
Eintrag öffnenKalydeco · 4.5 · Interaction studies have only been performed in adults.
Eintrag öffnenKalydeco · 4.5 · Interaction studies have only been performed in adults.
Eintrag öffnenKalydeco · 4.5 · Ivacaftor has been studied with an oestrogen/progesterone oral contraceptive and was found to have no signific
Eintrag öffnenKalydeco · 4.5 · Ivacaftor has been studied with an oestrogen/progesterone oral contraceptive and was found to have no signific
Eintrag öffnenKalydeco · 4.5 · Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, incre
Eintrag öffnenKalydeco · 4.5 · Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, incre
Eintrag öffnenKalydeco · 4.5 · Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P-glycoprotein (P-gp) and a
Eintrag öffnenKalydeco · 4.5 · Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P-glycoprotein (P-gp) and a
Eintrag öffnenKalydeco · 4.5 · Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended
Eintrag öffnenKalydeco · 4.5 · Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended
Eintrag öffnenKalydeco · 4.5 · Medicinal products affected by ivacaftor
Eintrag öffnenKalydeco · 4.5 · Medicinal products affecting the pharmacokinetics of ivacaftor
Eintrag öffnenKalydeco · 4.5 · Medicinal products affecting the pharmacokinetics of ivacaftor
Eintrag öffnenKalydeco · 4.5 · No dose adjustment is recommended when ivacaftor is used with moderate or weak CYP3A inducers.
Eintrag öffnenKalydeco · 4.5 · No dose adjustment is recommended when ivacaftor is used with moderate or weak CYP3A inducers.
Eintrag öffnenKalydeco · 4.5 · Paediatric population
Eintrag öffnenKalydeco · 4.5 · Paediatric population
Eintrag öffnenKalydeco · 4.5 · Potential for ivacaftor to interact with transporters
Eintrag öffnenKalydeco · 4.5 · Potential for ivacaftor to interact with transporters
Eintrag öffnen